BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that an abstract from its SUNRISE-PD study evaluating its lead candidate bezisterim (NE3107) for Parkinson’s disease has been accepted for presentation at the AD/PD 2026 Advances in Science & Therapy annual meeting.
The conference is scheduled to take place March 17 to 21, 2026, in Copenhagen, Denmark.
The abstract, titled “Demographics and Baseline Characteristics of Participants in a Study of Bezisterim (NE3107) in Early Parkinson’s Disease (SUNRISE-PD),” summarizes initial data on patients enrolled in the study and will be presented as a poster. Topline results from the SUNRISE-PD study are expected in mid-2026.
According to the company, the AD/PD Alzheimer’s Disease and Parkinson’s Disease Conference focuses on developments in treatment, translational research and development, early diagnosis, drug development, and clinical trials related to Alzheimer’s disease, Parkinson’s disease, and other neurological disorders.
Bezisterim (NE3107) is an oral drug designed to cross the blood-brain barrier and reduce inflammation while improving insulin sensitivity without suppressing the immune system. The therapy works by modulating pathways associated with neuroinflammation, including ERK, NFκB and TNF-α.
BioVie previously completed a Phase 2 study in Parkinson’s disease that evaluated bezisterim in combination with levodopa. According to the company, patients with moderate-to-severe Parkinson’s who received the drug alongside levodopa demonstrated improved motor control and fewer morning symptoms compared with those receiving levodopa alone, with few drug-related side effects observed.
The ongoing SUNRISE-PD study recently completed enrollment of 60 patients and is designed to assess whether bezisterim as a standalone therapy can improve motor and non-motor symptoms in Parkinson’s patients who have not yet been treated with carbidopa/levodopa.
BioVie is also evaluating bezisterim in other indications. The ADDRESS-LC trial for Long COVID is enrolling about 200 patients to determine whether the drug can reduce neurological symptoms such as brain fog and fatigue. In Alzheimer’s disease, the company has conducted Phase 2 and Phase 3 trials and reported early results suggesting improvements in cognition and biomarkers, supporting further research.
